High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury
暂无分享,去创建一个
[1] K. Ishak,et al. Diclofenac‐associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions , 1995, Hepatology.
[2] M. Waring. Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.
[3] T. Macdonald,et al. Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system. , 2007, Bioorganic & medicinal chemistry letters.
[4] J. Senior. Drug hepatotoxicity from a regulatory perspective. , 2007, Clinics in liver disease.
[5] M. Black,et al. Drug induced liver disease. , 1983, Postgraduate medical journal.
[6] William M. Lee,et al. Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.
[7] Chandan Saha,et al. Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals , 2008, Hepatology.
[8] Laura K. Schnackenberg,et al. The Liver Toxicity Biomarker Study: Phase I Design and Preliminary Results , 2009, Toxicologic pathology.
[9] M. Fielden,et al. The role of early in vivo toxicity testing in drug discovery toxicology. , 2008, Expert opinion on drug safety.
[10] J. Peters,et al. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.
[11] N. Chalasani,et al. Risk factors for idiosyncratic drug-induced liver injury. , 2010, Gastroenterology.
[12] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[13] D. Thompson,et al. Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.
[14] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[15] S. Majumdar,et al. Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.
[16] P Smith,et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.
[17] Alexander Golbraikh,et al. Combinatorial QSAR Modeling of P-Glycoprotein Substrates. , 2006 .
[18] Jill P. Smith,et al. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis c: a case series , 1998, American Journal of Gastroenterology.
[19] Weida Tong,et al. FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.
[20] J. Uetrecht,et al. Prediction of a new drug's potential to cause idiosyncratic reactions. , 2001, Current opinion in drug discovery & development.
[21] Min Zhang,et al. A decade of toxicogenomic research and its contribution to toxicological science. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[22] Min Zhang,et al. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? , 2012, Chemical research in toxicology.
[23] Nigel Greene,et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.
[24] F. Ballet. Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison. , 2010, Gastroenterologie clinique et biologique.
[25] E. Bjornsson,et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events , 2010, Hepatology.
[26] J. Borlak. 3.3 Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity – molecular mechanisms and lessons for pharmacotoxicity , 2009, Human & experimental toxicology.
[27] M. Waring. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.
[28] W. Tong,et al. Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. , 2009, Toxicology and applied pharmacology.
[29] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[30] Nigel Greene,et al. Developing structure-activity relationships for the prediction of hepatotoxicity. , 2010, Chemical research in toxicology.
[31] S. Kunte,et al. Statistical computing , 1999 .